Table 3 Factors associated with progression-free survival and overall survival
Variables | OS Univariate analysisMultivariate analysis | PFS Univariate analysis Multivariate analysis | |||||||
|---|---|---|---|---|---|---|---|---|---|
Log Rank | P-value | HR,95%CI | P-value | Log Rank | P-value | HR,95%CI | P-value | ||
Age of diagnosis | <65, ≥ 65 | 2.961 | 0.085 | -- | -- | 3.966 | 0.046 | -- | -- |
Age of menopause | <50, ≥50 | 0.003 | 0.953 | -- | -- | 0.157 | 0.692 | -- | -- |
parity | <2, ≥2 | 0.691 | 0.406 | -- | -- | 0.163 | 0.686 | -- | -- |
ER | Positive,negative | 0.731 | 0.393 | -- | -- | 0.148 | 0.701 | -- | -- |
PR | Positive,negative | 3.263 | 0.071 | -- | -- | 8.890 | 0.003 | -- | -- |
Histological composition | Pure USC, mixed USC | 0.420 | 0.517 | -- | -- | 4.474 | 0.034 | -- | -- |
CA-125 | Normal, elveted | 4.734 | 0.03 | 1.127 0.342–3.718 | 0.844 | 7.880 | 0.005 | 0.908 0.332–2.479 | 0.850 |
FIGO Stage | Early, advanced | 14.618 | <0.001 | 1.203 0.150–9.669 | 0.862 | 18.914 | <0.001 | 1.378 0.287–6.632 | 0.689 |
Surgery approach | Staged surgery, cytoreduction surgery | 17.280 | <0.001 | 2.676 1.061–6.751 | 0.037 | 31.125 | <0.001 | 1.543 0.755–3.151 | 0.234 |
Myometrial invasion depth | <1/2, ≥ 1/2 | 16.703 | <0.001 | 2.578 0.632–10.524 | 0.187 | 16.081 | <0.001 | 3.440 1.146–10.352 | 0.028 |
Adjuvant treatment | CT,CT and RT | 0.294 | 0.588 | -- | -- | 1.375 | 0.241 | -- | -- |
LVSI | Present, absent | 23.838 | <0.001 | 4.814 0.787–29.431 | 0.089 | 15.766 | <0.001 | 0.994 0.279–3.537 | 0.993 |
Lymph nodes metastasis | Present, absent | 27.693 | <0.001 | 7.316 1.080-49.565 | 0.041 | 29.364 | <0.001 | 3.374 0.790-14.406 | 0.101 |
Peritoneal cytology | Present, absent | 17.396 | <0.001 | 0.737 0.193–2.822 | 0.656 | 23.514 | <0.001 | 2.140 0.685–6.685 | 0.190 |